Navigation Links
Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant
Date:7/30/2014

SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. C1-INH is a human protein and an important inhibitor of the complement system.

The study shows that post-transplant treatment with C1-INH results in significant increases in the levels of complement components 3 and 4, suggesting that C1-INH inhibits activation of the complement system following transplantation. Antibody-mediated rejection is a major cause of kidney transplant failure and is often associated with activation of complement, a set of proteins that work with antibodies and play a role in the development of inflammation and tissue damage.

"Antibody-mediated rejection is a severe form of rejection that can occur in patients who have undergone a kidney transplant," said Stanley C. Jordan, M.D., Kidney Transplant, Cedars-Sinai Medical Center in Los Angeles, and one of the study's investigators. "Our findings provide additional insight into how C1-INH affects complement activation and represent an important advance in the study of complement-targeting therapeutics."

The placebo-controlled, single-center study evaluated 20 highly sensitized patients, meaning they already had antibodies against donor organs. Subjects were randomized to receive either placebo or 20 IU/kg of C1-INH, administered intra-operatively, then twice a week for seven additional doses. Patients were desensitized with immunoglobulin and rituximab, decreasing the patient's antibody levels prior to transplant.

According to study findings, fewer patients who were administered C1-INH developed serious adverse events compared to those administered placebo (20 percent versus 30 percent). C1-INH functi
'/>"/>

SOURCE CSL Behring
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 ... engaged in the development of high-value and difficult to ... will be presenting at the 21 st Annual ... New York . Bertrand Liang , chief ... the company,s development programs and business strategy on Friday, ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... SOMERSET, N.J., June 9 Alfacell Corporation,(Nasdaq: ACEL ... quarter,of fiscal 2008., The company recorded a net ... diluted common share, for the third fiscal quarter ended,April ... million, or $0.04,per basic and diluted common share, for ...
... Limited (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical ... lots of the ADHD patch DAYTRANA (lots,2750211 and ... DAYTRANA,patches do not meet their release liner removal ... have difficulties removing the,liners. This voluntary recall is ...
... 9 Amira Pharmaceuticals, a small,molecule pharmaceutical company ... treat inflammatory diseases, announced the hiring of Michael,V. ... Swanson has over 30 years of experience in ... in life sciences and specialty,pharmaceutical companies. Prior to ...
Cached Biology Technology:Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 2Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 3Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 4Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 5Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 6Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 2Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 3Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 4Amira Pharmaceuticals Hires Industry Veteran for CFO Position 2
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University is proving its potential to impact global health. ... journal PLoS ONE , Rice alumnus Andrew Miller ... which costs $240, stacks up nicely against devices that ... of tuberculosis. Miller and colleagues at The Methodist ...
... not recognized as an animal until the 19th century, is ... have their genome sequenced. In a paper appearing in ... a team of researchers led by Daniel Rokhsar of the ... Genome Institute (JGI), report the draft genome sequence of the ...
... How well do you understand life in your own backyard? Cities ... aren,t visitors; they are an integral component, like trees in a ... the Earth,s people live in cities and the amount of paved ... Ohio, shouldn,t our sciences thrive in the city? Urban Ecosystem ...
Cached Biology News:Compact microscope a marvel 2Compact microscope a marvel 3Genome of ancient sponge reveals origins of first animals, cancer 2Genome of ancient sponge reveals origins of first animals, cancer 3Genome of ancient sponge reveals origins of first animals, cancer 4The real urban jungle 2
... system is used for single-color real-time detection ... or JOE fluorophores and features a real-time ... data from 96 wells, a gene expression ... analysis. The system includes the optical module ...
... Precision-designed for Optimal Microdissection , CapSure HS ... precise and rapid extraction of populations of ... samples with Laser Capture Microdissection., Ensure ... Molecular Analysis , All CapSure LCM Caps ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... systems are highly sensitive laser confocal systems ... are advanced scanners that meet your expectations, ... level, and optimizing the signal on the ... of the range for increased sensitivity. Results ...
Biology Products: